Accès libre

Assessment of retracted papers, and their retraction notices, from a cancer journal associated with “paper mills”

À propos de cet article

Citez

Introduction

Cancer and oncology researches are stated as being in a replication and trust crisis (Errington et al., 2021; Teixeira da Silva, 2022). Plagued by issues related to replication, fraud, misconduct, paper mill-derived research and cross-publication forgeries, as well as failed peer review and editorial handling, the number of retracted papers related to cancer research has continued to climb (Pantziarka & Meheus, 2019; Retraction Watch, 2022). A salient example, Tumor Biology, had one of the highest retraction rates among biomedical journals, many as a result of fake peer review (Bhatt, 2021). Fake peer review (Rivera & Teixeira da Silva, 2021) and paper mill-derived fraud (Else & Van Noorden, 2021) threaten the integrity of and trust in the literature and industry (COPE & STM, 2022). Authors citing retracted literature might not always be aware that they are doing so (De Cassai et al., 2022).

The objective of this study was to appreciate some metrics- and indexing-related factors of papers that have been retracted from an indexed cancer journal, Cancer Biotherapy and Radiopharmaceuticals (CB&R), published by Mary Ann Liebert, Inc., and to gain an appreciation of the weight of “paper mills” in this body of retractions. We were spurred to analyze CB&R due to the public comments by Susan Jensen, the director of production and editorial operations at Mary Ann Liebert, Inc., who indicated that CB&R was identifying, and rejecting, papers that may have been derived from paper mills. This study attempts to better appreciate CB&R retractions associated with paper mills, and the “quality” of their retraction notices (RNs).

Data and methods

The CB&R website was searched between July 5 and 10, 2022, to identify retractions in this journal. Details were confirmed manually, and against the Retraction Watch database (Retraction Watch, 2022). Scopus and Web of Science were also consulted (July 10, 2022) to try and draw any additional information of potential interest that could not be gleaned from either the CB&R website, or the Retraction Watch database. Background data for all of these aspects of the retracted papers can be found in the Supplementary Table.

Results and discussion
Properties of 23 CB&R retractions

We identified 23 retractions in CB&R, all original articles whose authors had an affiliation in China (i.e., 100%), and 52/73 (71%) of those affiliations were associated with hospitals (Table 1). This finding closely mirrors a trend observed by Zhao et al. (2021). None of the RNs are pay-walled, and three of the RNs have a correction. Four of the RNs explicitly indicate paper mills as a reason for retraction, but the vast majority of papers were retracted for integrity-based issues related to raw data, data manipulation, or breach of data-related policies (Table 1). In Scopus, the retracted status of 17% of the 23 retracted papers is not indicated. For another four papers, the RN is available only when viewing the full description of the document, which might be confusing for Scopus users.

Cancer Biotherapy and Radiopharmaceuticals retractions (until July 10, 2022), including reason(s) for retraction and country of authors, according to Retraction Watch (2022). In addition, retraction notices were consulted to appreciate if retractions were induced by the authors, or by the editor/publisher. Finally, the number of affiliations associated with a hospital was noted.

DOI Reason(s) for retraction1 Explicit author-induced? # Hospital affiliations**
https://doi.org/10.1089/cbr.2019.3275 Irreproducible results Yes 4/5
https://doi.org/10.1089/cbr.2019.3520 Concerns/issues about data/results; paper mill* Yes 4/5
https://doi.org/10.1089/cbr.2014.1766 Concerns/issues about data/image; investigations/objection by third party No 1/1
https://doi.org/10.1089/cbr.2014.1723 Concerns/issues about data/image; investigations/objection by third party; error in text No 1/1
https://doi.org/10.1089/cbr.2019.3535 Image falsification/fabrication; miscommunication by third party; original data not provided; paper mill* No 4/4
https://doi.org/10.1089/cbr.2020.3563 Concerns/issues about third party involvement; image duplication; data falsification/fabrication; miscommunication by third party No 4/6
https://doi.org/10.1089/cbr.2019.3299 Breach of policy by author; original data not provided; paper mill No 1/1
https://doi.org/10.1089/cbr.2014.1698 Data/text duplication; paper mill* No 5/9
https://doi.org/10.1089/cbr.2014.1728 Data/text duplication; paper mill* No 1/1
https://doi.org/10.1089/cbr.2014.1759 Data/text duplication; paper mill* No 1/2
https://doi.org/10.1089/cbr.2014.1778 Data/text duplication; paper mill* No 2/3
https://doi.org/10.1089/cbr.2017.2306 Breach of policy by author; paper mill No 1/1
https://doi.org/10.1089/cbr.2017.2386 Misconduct by third party; paper mill Yes 2/2
https://doi.org/10.1089/cbr.2018.2625 Unreliable results; paper mill No 1/1
https://doi.org/10.1089/cbr.2018.2626 Breach of policy by author; paper mill No 1/1
https://doi.org/10.1089/cbr.2018.2664 Breach of policy by author; paper mill No 2/2
https://doi.org/10.1089/cbr.2018.2749 Paper mill No 2/2
https://doi.org/10.1089/cbr.2019.2858 Paper mill No 5/5
https://doi.org/10.1089/cbr.2019.2983 Paper mill No 2/4
https://doi.org/10.1089/cbr.2019.3070 Breach of policy by author; paper mill No 2/4
https://doi.org/10.1089/cbr.2018.2545 Concerns/issues about data/image; original data not provided; paper mill No 3/3
https://doi.org/10.1089/cbr.2017.2432 Concerns/issues about data/image; original data not provided; paper mill No 2/3
https://doi.org/10.1089/cbr.2015.1952 Concerns/issues about authorship/data/image/results/third party involvement; paper mill* No 1/2

Reasons, and wording of reasons, modified from the original statements at Retraction Watch after close examination of the reasons and the papers/websites.

* The term “paper mill” does not appear in the original retraction notice.

** All affiliations from all papers were from China.

Emails and identities of authors of retracted CB&R papers

In addition to the association between paper mill-derived cancer research and affiliations that are Chinese hospitals, the use of web-based emails is also characteristic (Else & Van Noorden, 2021; Liu & Chen, 2021; Teixeira da Silva, 2021; Zhao et al., 2021). Corresponding authors’ emails were missing from 4/23 papers on the publisher’s website, one paper had three corresponding authors, but none had institutional emails, 12/21 (57%) emails were @163.com (5/21 were @126.com; 4/21 were @sina.com), and 9/21 (43%) emails had prefixes or names that were unrelated to the corresponding author’s name (Suppl. Table 1).

The CB&R instructions for authors (IFA) made no specific mention of email-related limitations (CB&R, 2022). Another cancer journal, Tumor Biology, published by IOS Press, explicitly prohibited the use of web-based emails for submission, stating: “The journal does not accept submissions from authors using nondescript, anonymous, email addresses (e.g., yahoo.com, gmail.com, 163.com, rediffmail.com, sina.com, 126.com, hotmail.com, etc.).” (Tumor Biology, 2022). No ORCID (Open Researcher and Contributor ID) for any corresponding author was identified in all 23 retracted papers, even though the CB&R IFA indicated that ORCID is mandatory for corresponding authors: “All submitting authors are required to complete their submissions using an ORCID identifier” (CB&R, 2022). The existence of blank or disposable (one-time use) ORCIDs, as are sometimes observed in paper mill-derived papers, degrade trust in the validity of author-based identifiers (Teixeira da Silva, 2022b).

The citation of retracted literature

According to Web of Science Core Collection Citations, the 23 retracted papers accumulated (until March 23, 2023) 287 citations (253 according to Scopus and 365 according to Google Scholar). At the same time, these papers continue to receive citations after the retraction: 54 citations according to Web of Science Core Collection, 54 according to Scopus, and 77 according to Google Scholar. Some retracted cancer papers continue to accrue positive (i.e., supporting) citations, although these tend to wane after the second year, and dip to near-zero citations after about a decade (Hamilton, 2019). Just over 55% of 12,231 Web of Science-indexed retracted papers published between 1981 and 2020 were cited at least once, about a quarter of which were self-citations (Sharma, 2021). Sharma (2021) also noted that Cancer Research had accrued 106 retractions that were cited on average 46 times. The reasons why authors cite retracted papers are not always clear (Dal-Ré & Ayuso, 2021), although the citation of older retracted papers tends to wane over time (Hsiao & Schneider, 2022).

Limited information in retraction notices limits their usefulness

We believe that more detailed information in the RNs would have made them more informative. Missing information from a RN, incomplete RNs, or RNs that are opaque or unclear do not benefit academia, and are a poor instrument of information (Teixeira da Silva & Vuong, 2022; Xu & Hu, 2022). In our view, a complete and informative RN – irrespective of its size – would have all of the following components to be both informative and transparent, holding the relevant parties accountable: 1) global appreciation of each concern and how it impacts the integrity of the paper, or its data; 2) an understanding of how the concerns came to light; 3) dates of any and all communication between all relevant parties; 4) outcomes of queries and – where possible – perspectives and responses of authors and editors.

Study limitation

This research note has a limitation, having focused on only one cancer-related journal (CB&R), and only on 23 retractions and their associated RNs.

eISSN:
2543-683X
Langue:
Anglais